Exploring the role of TERT in thyroid Cancer: A systematic review

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2025-06-06 DOI:10.1016/j.critrevonc.2025.104792

Thais Maloberti , Andrea Repaci , Laura Poppi , Floriana Jessica Di Paola , Giulia Calafato , Sara Coluccelli , Francesca Carosi , Alessandra Colapinto , Simone Colombero , Giacomo Credi , Giovanni Tallini , Maria A. Pantaleo , Margherita Nannini , Dario de Biase

{"title":"Exploring the role of TERT in thyroid Cancer: A systematic review","authors":"Thais Maloberti , Andrea Repaci , Laura Poppi , Floriana Jessica Di Paola , Giulia Calafato , Sara Coluccelli , Francesca Carosi , Alessandra Colapinto , Simone Colombero , Giacomo Credi , Giovanni Tallini , Maria A. Pantaleo , Margherita Nannini , Dario de Biase","doi":"10.1016/j.critrevonc.2025.104792","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><em>TERT</em> gene mutations play critical roles in tumor progression and have important implications in several solid tumors, including thyroid carcinoma. This study aimed to evaluate the association between <em>TERT</em> promoter mutations and histology and clinical features of thyroid carcinoma (TC).</div></div><div><h3>Materials and methods</h3><div>We performed an up-to-date systematic review and a comprehensive meta-analysis. Systematic searches were made on MEDLINE (via Pubmed) databases using relevant keywords, and articles published until November 1st, 2024 were selected. A total of 54 studies and 17’021 samples are included in the meta-analysis. Relevant data for the meta-analysis was extracted, and for statistical analysis, chi-square calculation was used.</div></div><div><h3>Results</h3><div>Thyroid carcinomas with the highest frequency of <em>TERT</em> mutations are Anaplastic thyroid carcinoma (55.8 %) and Diffuse sclerosing variant of papillary thyroid carcinoma (60.4 %). No <em>TERT</em> mutations founds in Benign neoplasm, NIFTP and Medullary thyroid carcinoma. Mutations with the highest frequency is c.–124C>T (chr5:1295228 - C228T). <em>TERT</em> mutations are statistically correlated with Stage III&IV, presence of metastasis, overall survival, recurrence and radioiodine-refractory.</div></div><div><h3>Conclusion</h3><div><em>TERT</em> mutation plays a crucial role as a prognostic biomarker with tumor aggressiveness. Thus, in clinical practice, mutational status assessment of the <em>TERT</em> promoter should be considered for accurate prognostic stratification of TCs.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"213 ","pages":"Article 104792"},"PeriodicalIF":5.5000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842825001805","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

TERT gene mutations play critical roles in tumor progression and have important implications in several solid tumors, including thyroid carcinoma. This study aimed to evaluate the association between TERT promoter mutations and histology and clinical features of thyroid carcinoma (TC).

Materials and methods

We performed an up-to-date systematic review and a comprehensive meta-analysis. Systematic searches were made on MEDLINE (via Pubmed) databases using relevant keywords, and articles published until November 1st, 2024 were selected. A total of 54 studies and 17’021 samples are included in the meta-analysis. Relevant data for the meta-analysis was extracted, and for statistical analysis, chi-square calculation was used.

Results

Thyroid carcinomas with the highest frequency of TERT mutations are Anaplastic thyroid carcinoma (55.8 %) and Diffuse sclerosing variant of papillary thyroid carcinoma (60.4 %). No TERT mutations founds in Benign neoplasm, NIFTP and Medullary thyroid carcinoma. Mutations with the highest frequency is c.–124C>T (chr5:1295228 - C228T). TERT mutations are statistically correlated with Stage III&IV, presence of metastasis, overall survival, recurrence and radioiodine-refractory.

Conclusion

TERT mutation plays a crucial role as a prognostic biomarker with tumor aggressiveness. Thus, in clinical practice, mutational status assessment of the TERT promoter should be considered for accurate prognostic stratification of TCs.

查看原文本刊更多论文

探讨TERT在甲状腺癌中的作用：一项系统综述。

背景：TERT基因突变在肿瘤进展中起关键作用，在包括甲状腺癌在内的几种实体肿瘤中具有重要意义。本研究旨在评估TERT启动子突变与甲状腺癌（TC）的组织学和临床特征之间的关系。材料和方法：我们进行了最新的系统综述和全面的荟萃分析。利用相关关键词在MEDLINE（通过Pubmed）数据库进行系统检索，选取2024年11月1日前发表的文章。meta分析共纳入54项研究和17021个样本。提取meta分析相关资料，采用卡方计算进行统计分析。结果：TERT突变发生率最高的甲状腺癌为间变性甲状腺癌（55.8%）和弥漫性硬化型甲状腺乳头状癌（60.4%）。良性肿瘤、NIFTP和甲状腺髓样癌中未发现TERT突变。突变频率最高的是c - 124c >T （chr5:1295228 - C228T）。TERT突变与iii期和iv期、转移、总生存、复发和放射性碘难治性有统计学相关性。结论：TERT突变是肿瘤侵袭性预后的重要生物标志物。因此，在临床实践中，应考虑对TERT启动子的突变状态进行评估，以便对tc进行准确的预后分层。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.